S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
OTCMKTS:ADXS

Ayala Pharmaceuticals - ADXS Stock Forecast, Price & News

$1.35
-0.15 (-10.00%)
(As of 03/24/2023 08:52 PM ET)
Add
Compare
Today's Range
$1.30
▼
$1.40
50-Day Range
$1.30
▼
$1.80
52-Week Range
$1.00
▼
$10.71
Volume
1,000 shs
Average Volume
7,684 shs
Market Capitalization
$2.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADXS stock logo

About Ayala Pharmaceuticals (OTCMKTS:ADXS) Stock

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

March 27, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Receives New Coverage from Analysts at StockNews.com
March 26, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)
March 27, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 23, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)
March 21, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Research Coverage Started at StockNews.com
March 18, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Earns Sell Rating from Analysts at StockNews.com
March 3, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
February 10, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
March 27, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
January 19, 2023 | finance.yahoo.com
Advaxis and Ayala Pharmaceuticals Complete Merger
December 25, 2022 | finance.yahoo.com
Advaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo Finance
October 20, 2022 | streetinsider.com
Form 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.com
October 20, 2022 | finance.yahoo.com
RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo Finance
October 19, 2022 | benzinga.com
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - Benzinga
October 19, 2022 | businesswire.com
AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
October 19, 2022 | baystreet.ca
Ayala, Advaxis Merge - Baystreet.ca
October 19, 2022 | marketwatch.com
Ayala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatch
October 19, 2022 | finance.yahoo.com
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement - Yahoo Finance
October 19, 2022 | seekingalpha.com
Ayala stock rises 16% on all-stock merger with Advaxis to focus on cancer drugs - Seeking Alpha
October 19, 2022 | globenewswire.com
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswire
October 17, 2022 | globenewswire.com
Rich Insights into the Metastatic Urothelial Carcinoma Clinical Trial Analysis Featuring 40+ Companies and Therapies | DelveInsight - GlobeNewswire
October 13, 2022 | globenewswire.com
Herbal Medicinal Products Market Is Expected to Grasp the Value of USD 177.65 Billion with Growing CAGR of 6.83% by 2029, Size, Shares, Trends, Growth and Revenue Outlook - GlobeNewswire
October 4, 2022 | finance.yahoo.com
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Yahoo Finance
October 4, 2022 | benzinga.com
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Benzinga
September 28, 2022 | streetinsider.com
Reunion Neuroscience (REUN) Appoints Greg Mayes as President and CEO - StreetInsider.com
September 28, 2022 | finance.yahoo.com
Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer
September 28, 2022 | markets.businessinsider.com
Reunion Neuroscience Names Greg Mayes As President And CEO
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Company Calendar

Last Earnings
9/09/2021
Today
3/26/2023
Next Earnings (Estimated)
6/06/2023
Fiscal Year End
10/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ADXS
CUSIP
N/A
CIK
1100397
Web
www.advaxis.com
Phone
(609) 452-9813
Fax
609-452-9818
Employees
14
Year Founded
2002

Profitability

EPS (Most Recent Fiscal Year)
($8.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,860,000.00
Net Margins
N/A
Pretax Margin
-6,064.80%
Return on Equity
-54.02%
Return on Assets
-47.27%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.64
Quick Ratio
15.64

Sales & Book Value

Annual Sales
$3.24 million
Price / Sales
0.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$21.36 per share
Price / Book
0.06

Miscellaneous

Outstanding Shares
1,816,000
Free Float
1,811,000
Market Cap
$2.45 million
Optionable
Optionable
Beta
2.44

Social Links


Key Executives

  • Ken Berlin
    President, Chief Executive Officer & Director
  • Igor Gitelman
    VP-Finance, Chief Financial & Accounting Officer
  • Andres A. Gutiérrez
    Chief Medical Officer & Executive Vice President
  • Michael Grace
    Vice President-Technical Operations

Key Competitors

View All Competitors













ADXS Stock - Frequently Asked Questions

How have ADXS shares performed in 2023?

Ayala Pharmaceuticals' stock was trading at $1.20 on January 1st, 2023. Since then, ADXS stock has increased by 12.5% and is now trading at $1.35.
View the best growth stocks for 2023 here.

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023.
View our ADXS earnings forecast.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) posted its quarterly earnings results on Thursday, September, 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The biotechnology company earned $0.25 million during the quarter.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ADXS."

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ayala Pharmaceuticals' stock price today?

One share of ADXS stock can currently be purchased for approximately $1.35.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals (OTCMKTS:ADXS) has a market capitalization of $2.45 million and generates $3.24 million in revenue each year. The biotechnology company earns $-17,860,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The official website for the company is www.advaxis.com. The biotechnology company can be reached via phone at (609) 452-9813, via email at ir@advaxis.com, or via fax at 609-452-9818.

This page (OTCMKTS:ADXS) was last updated on 3/27/2023 by MarketBeat.com Staff